Now showing items 1418-1437 of 2862

    • L-serine in disease and development 

      De Koning, TJ; Snell, K; Duran, M; Berger, R; Poll-The, BT; Surtees, R (PORTLAND PRESS LTD, 2003-05-01)
      The amino acid L-serine, one of the so-called non-essential amino acids, plays a central role in cellular proliferation. L-Serine is the predominant source of one-carbon groups for the de novo synthesis of purine nucleotides ...
    • Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer. 

      Tokaca, N; Wotherspoon, A; Nicholson, AG; Fotiadis, N; Thompson, L; Popat, S (2017-09)
      Small cell transformation is a rare but well recognised mechanism of acquired resistance to EGFR-TKI therapy in EGFR-mutated NSCLC, but optimal drug therapy thereof is unknown. Nivolumab has demonstrated activity in relapsed ...
    • Landscape of somatic mutations in 560 breast cancer whole-genome sequences. 

      Nik-Zainal, S; Davies, H; Staaf, J; Ramakrishna, M; Glodzik, D; Zou, X; Martincorena, I; Alexandrov, LB; Martin, S; Wedge, DC; Van Loo, P; Ju, YS; Smid, M; Brinkman, AB; Morganella, S; Aure, MR; Lingjærde, OC; Langerød, A; Ringnér, M; Ahn, SM; Boyault, S; Brock, JE; Broeks, A; Butler, A; Desmedt, C; Dirix, L; Dronov, S; Fatima, A; Foekens, JA; Gerstung, M; Hooijer, GK; Jang, SJ; Jones, DR; Kim, HY; King, TA; Krishnamurthy, S; Lee, HJ; Lee, JY; Li, Y; McLaren, S; Menzies, A; Mustonen, V; O'Meara, S; Pauporté, I; Pivot, X; Purdie, CA; Raine, K; Ramakrishnan, K; Rodríguez-González, FG; Romieu, G; Sieuwerts, AM; Simpson, PT; Shepherd, R; Stebbings, L; Stefansson, OA; Teague, J; Tommasi, S; Treilleux, I; Van den Eynden, GG; Vermeulen, P; Vincent-Salomon, A; Yates, L; Caldas, C; van't Veer, L; Tutt, A; Knappskog, S; Tan, BK; Jonkers, J; Borg, Å; Ueno, NT; Sotiriou, C; Viari, A; Futreal, PA; Campbell, PJ; Span, PN; Van Laere, S; Lakhani, SR; Eyfjord, JE; Thompson, AM; Birney, E; Stunnenberg, HG; van de Vijver, MJ; Martens, JW; Børresen-Dale, AL; Richardson, AL; Kong, G; Thomas, G; Stratton, MR (2016-06)
      We analysed whole-genome sequences of 560 breast cancers to advance understanding of the driver mutations conferring clonal advantage and the mutational processes generating somatic mutations. We found that 93 protein-coding ...
    • Large Interobserver Variation in the International MR-LINAC Oropharyngeal Carcinoma Delineation Study 

      Blinde, S; Mohamed, ASR; Al-Mamgani, A; Newbold, K; Karam, I; Robbins, JR; Thomson, D; Fuller, CD; Raaijmakers, CP; Terhaard, C (2017-10-01)
    • Large-scale Analysis Demonstrates Familial Testicular Cancer to have Polygenic Aetiology. 

      Loveday, C; Law, P; Litchfield, K; Levy, M; Holroyd, A; Broderick, P; Kote-Jarai, Z; Dunning, AM; Muir, K; Peto, J; Eeles, R; Easton, DF; Dudakia, D; Orr, N; Pashayan, N; UK Testicular Cancer Collaboration, The PRACTICAL Consortium; Reid, A; Huddart, RA; Houlston, RS; Turnbull, C (2018-09)
      Testicular germ cell tumour (TGCT) is the most common cancer in young men. Multiplex TGCT families have been well reported and analyses of population cancer registries have demonstrated a four- to eightfold risk to male ...
    • Large-scale genotyping identifies 41 new loci associated with breast cancer risk. 

      Michailidou, K; Hall, P; Gonzalez-Neira, A; Ghoussaini, M; Dennis, J; Milne, RL; Schmidt, MK; Chang-Claude, J; Bojesen, SE; Bolla, MK; Wang, Q; Dicks, E; Lee, A; Turnbull, C; Rahman, N; Fletcher, O; Peto, J; Gibson, L; Dos Santos Silva, I; Nevanlinna, H; Muranen, TA; Aittomäki, K; Blomqvist, C; Czene, K; Irwanto, A; Liu, J; Waisfisz, Q; Meijers-Heijboer, H; Adank, M; van der Luijt, RB; Hein, R; Dahmen, N; Beckman, L; Meindl, A; Schmutzler, RK; Müller-Myhsok, B; Lichtner, P; Hopper, JL; Southey, MC; Makalic, E; Schmidt, DF; Uitterlinden, AG; Hofman, A; Hunter, DJ; Chanock, SJ; Vincent, D; Bacot, F; Tessier, DC; Canisius, S; Wessels, LF; Haiman, CA; Shah, M; Luben, R; Brown, J; Luccarini, C; Schoof, N; Humphreys, K; Li, J; Nordestgaard, BG; Nielsen, SF; Flyger, H; Couch, FJ; Wang, X; Vachon, C; Stevens, KN; Lambrechts, D; Moisse, M; Paridaens, R; Christiaens, MR; Rudolph, A; Nickels, S; Flesch-Janys, D; Johnson, N; Aitken, Z; Aaltonen, K; Heikkinen, T; Broeks, A; Veer, LJ; van der Schoot, CE; Guénel, P; Truong, T; Laurent-Puig, P; Menegaux, F; Marme, F; Schneeweiss, A; Sohn, C; Burwinkel, B; Zamora, MP; Perez, JI; Pita, G; Alonso, MR; Cox, A; Brock, IW; Cross, SS; Reed, MW; Sawyer, EJ; Tomlinson, I; Kerin, MJ; Miller, N; Henderson, BE; Schumacher, F; Le Marchand, L; Andrulis, IL; Knight, JA; Glendon, G; Mulligan, AM; Lindblom, A; Margolin, S; Hooning, MJ; Hollestelle, A; van den Ouweland, AM; Jager, A; Bui, QM; Stone, J; Dite, GS; Apicella, C; Tsimiklis, H; Giles, GG; Severi, G; Baglietto, L; Fasching, PA; Haeberle, L; Ekici, AB; Beckmann, MW; Brenner, H; Müller, H; Arndt, V; Stegmaier, C; Swerdlow, A; Ashworth, A; Orr, N; Jones, M; Figueroa, J; Lissowska, J; Brinton, L; Goldberg, MS; Labrèche, F; Dumont, M; Winqvist, R; Pylkäs, K; Jukkola-Vuorinen, A; Grip, M; Brauch, H; Hamann, U; Brüning, T; Radice, P; Peterlongo, P; Manoukian, S; Bonanni, B; Devilee, P; Tollenaar, RA; Seynaeve, C; van Asperen, CJ; Jakubowska, A; Lubinski, J; Jaworska, K; Durda, K; Mannermaa, A; Kataja, V; Kosma, VM; Hartikainen, JM; Bogdanova, NV; Antonenkova, NN; Dörk, T; Kristensen, VN; Anton-Culver, H; Slager, S; Toland, AE; Edge, S; Fostira, F; Kang, D; Yoo, KY; Noh, DY; Matsuo, K; Ito, H; Iwata, H; Sueta, A; Wu, AH; Tseng, CC; Van Den Berg, D; Stram, DO; Shu, XO; Lu, W; Gao, YT; Cai, H; Teo, SH; Yip, CH; Phuah, SY; Cornes, BK; Hartman, M; Miao, H; Lim, WY; Sng, JH; Muir, K; Lophatananon, A; Stewart-Brown, S; Siriwanarangsan, P; Shen, CY; Hsiung, CN; Wu, PE; Ding, SL; Sangrajrang, S; Gaborieau, V; Brennan, P; McKay, J; Blot, WJ; Signorello, LB; Cai, Q; Zheng, W; Deming-Halverson, S; Shrubsole, M; Long, J; Simard, J; Garcia-Closas, M; Pharoah, PD; Chenevix-Trench, G; Dunning, AM; Benitez, J; Easton, DF (2013-04)
      Breast cancer is the most common cancer among women. Common variants at 27 loci have been identified as associated with susceptibility to breast cancer, and these account for ∼9% of the familial risk of the disease. We ...
    • Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. 

      Campbell, J; Ryan, CJ; Brough, R; Bajrami, I; Pemberton, HN; Chong, IY; Costa-Cabral, S; Frankum, J; Gulati, A; Holme, H; Miller, R; Postel-Vinay, S; Rafiq, R; Wei, W; Williamson, CT; Quigley, DA; Tym, J; Al-Lazikani, B; Fenton, T; Natrajan, R; Strauss, SJ; Ashworth, A; Lord, CJ (2016-03-02)
      One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile genetic dependencies in cancer cell lines. Here, we describe data from a series of siRNA screens that identify the kinase ...
    • Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene. 

      Litchfield, K; Loveday, C; Levy, M; Dudakia, D; Rapley, E; Nsengimana, J; Bishop, DT; Reid, A; Huddart, R; Broderick, P; Houlston, RS; Turnbull, C (2018-06)
      Testicular germ cell tumour (TGCT), the most common cancer in young men, has a significant heritable basis that has long raised questions as to the existence of underlying major high-penetrance susceptibility gene(s). To ...
    • Large-scale transcriptome-wide association study identifies new prostate cancer risk regions. 

      Mancuso, N; Gayther, S; Gusev, A; Zheng, W; Penney, KL; Kote-Jarai, Z; Eeles, R; Freedman, M; Haiman, C; Pasaniuc, B; PRACTICAL consortium (2018-10-04)
      Although genome-wide association studies (GWAS) for prostate cancer (PrCa) have identified more than 100 risk regions, most of the risk genes at these regions remain largely unknown. Here we integrate the largest PrCa GWAS ...
    • Laryngeal cancer: United Kingdom National Multidisciplinary guidelines. 

      Jones, TM; De, M; Foran, B; Harrington, K; Mortimore, S (2016-05)
      This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. Significantly new data have been published on laryngeal cancer management since the ...
    • Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials. 

      Haviland, JS; Mannino, M; Griffin, C; Porta, N; Sydenham, M; Bliss, JM; Yarnold, JR; START Trialists' Group (2018-01)
      BACKGROUND AND PURPOSE: Adjuvant lymphatic radiotherapy (LNRT) is recommended for selected axillary node positive women with early breast cancer. We investigated whether hypofractionated LNRT is safe combined with ...
    • LAUNCH OF THE BREAST SCREENING AFTER RADIOTHERAPY DATASET - AN ENGLAND WIDE INITIATIVE TO IMPROVE SCREENING FOR BREAST CANCER IN 9,000 WOMEN AT HIGH RISK FOLLOWING RADIOTHERAPY TO BREAST TISSUE UNDER AGE 36 

      Radford, J; Howell, S; Vaughan, K; Goode, V; Worthington, D; Yates-Bolton, N; Payne, E; Jenkins, J; Sibbering, M; Swerdlow, A; Cowan, R (2016-10)
    • Lead-time in the European Randomised Study of Screening for Prostate Cancer 

      Finne, P; Fallah, M; Hakama, M; Ciatto, S; Hugosson, J; de Koning, H; Moss, S; Nelen, V; Auvinen, A (ELSEVIER SCI LTD, 2010-11)
      Background: Lead-time is defined as the time by which screening advances the diagnosis compared with absence of screening. A sufficiently long lead-time needs to be achieved so that cancer can be detected while still ...
    • Length of FMR1 repeat alleles within the normal range does not substantially affect the risk of early menopause. 

      Ruth, KS; Bennett, CE; Schoemaker, MJ; Weedon, MN; Swerdlow, AJ; Murray, A (2016-10)
      Is the length of FMR1 repeat alleles within the normal range associated with the risk of early menopause?The length of repeat alleles within the normal range does not substantially affect risk of early menopause.There is ...
    • Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. 

      O'Reilly, A; Larkin, J (2017-03)
      INTRODUCTION: In patients with mRCC options for second line therapies, following progression on anti-angiogenic agents, that demonstrate a survival advantage in clinical trials have been limited. Recently a number of agents ...
    • Lessons from a case of T-cell large granular lymphocytic leukaemia suggesting that immunomodulatory therapy is more effective than intensive treatment 

      Osuji, N; Matutes, E; Wotherspoon, A; Catovsky, D (2005-02)
      Leukemia treatment strives to eradicate the malignant clone. With T-cell large granular lymphocytic (LGL) leukemia, the onus of treatment appears to be modification of the disease rather than eradication of the clone, We ...
    • Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma. 

      Helgadottir, H; Kis, L; Ljungman, P; Larkin, J; Kefford, R; Ascierto, PA; Hansson, J; Masucci, G (2017-07-01)
    • Leukemic transformation by the APL fusion protein PRKAR1A-RAR alpha critically depends on recruitment of RXR alpha 

      Qiu, JJ; Lu, X; Zeisig, BB; Ma, Z; Cai, X; Chen, S; Gronemeyer, H; Tweardy, DJ; So, CWE; Dong, S (AMER SOC HEMATOLOGY, 2010-01-21)
      PRKAR1A (R1A)-retinoic acid receptor-alpha (R1A-RAR alpha) is the sixth RAR alpha-containing fusion protein in acute promyelocytic leukemia (APL). Using the murine bone-marrow retroviral transduction/transformation assay, ...